Physician profile

Robert A Christenson

Pediatric Endocrinology · El Paso, TX

NPI 1417940982

$186.01

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$75.62

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Insulet Corporation $45.85 2022-2023 Omnipod
Medtronic, INC. $45.13 2021-2023 Inpen Smart Insulin Delivery System
Ascendis Pharma Endocrinology INC $26.85 2022
Xeris Pharmaceuticals, INC. $24.01 2023 Gvoke Hypopen
Tandem Diabetes Care, INC. $16.58 2024 T:Slim X2 Insulin Pump With Control-Iq
Integra Lifesciences Corporation $14.47 2019
Abbvie INC. $13.12 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert A Christenson

$186.01

in general payments reported 2019-2025

Years
2019-2024
Top company
Insulet Corporation

https://glasscript.com/doctor/1030263/robert-a-christenson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.